Chronic myeloid leukemia · 5 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Imatinib monotherapy Variant #17 | — | R 27 014 | 30d | ~20.0 mo | ~53.0 mo | ~21 | ~R 567 284 PFS proxy · indirect | 8 |
Dasatinib monotherapy Variant #01 | — | R 12 899 | 28d | — | — | — | — | — |
Hydroxyurea and Plicamycin Variant #01 | — | R 794 | 21d | — | — | — | — | — |
Vincristine and Prednisone Variant #01 | — | R 183 | 5d | — | — | — | — | — |
Bosutinib monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
5 of 5 regimens shown